Physician Views snap-poll: Are oncologists embracing NTRK as a biomarker?

The significance of new drugs designed to treat solid tumours caused by a specific genetic mutation regardless of where they are located in the body was highlighted again last week when abstracts were released ahead of this year's ASCO annual meeting, which takes place at the end of the month.

Among the most high-profile data presentations will be updated clinical results for Roche's entrectinib. More here.

Entrectinib has been granted priority review by the FDA for the treatment of certain patients with NTRK fusion-positive, locally advanced or metastatic solid tumours and those with metastatic ROS1-positive non-small-cell lung cancer. An approval decision is expected by August.

However, a similar product Vitrakvi (larotrectinib) - developed by Loxo Oncology and marketed by Bayer - was approved by the FDA last November.

Our latest Physician Views snap poll will gauge how US oncologists have responded to its approval during the past six months…

Q. How would you rate your awareness of Vitrakvi (larotrectinib), an approved therapy for the treatment of solid tumours harbouring a neurotrophic receptor tyrosine kinase (NTRK) gene fusion?

Not at all aware

Slightly aware

Somewhat aware

Moderately aware

Extremely aware

_______

Q. The FDA approved Vitrakvi back in November for the treatment of advanced solid tumours harbouring a NTRK gene fusion.

How frequently do you test relevant cancer patients for NTRK gene fusions to see if they are eligible for treatment with this drug?

Never

Rarely

Sometimes

Often

Always

_______

Q. Is a lack of access to NTRK gene fusion testing acting as a barrier to your utilisation of Vitrakvi ?

Not a barrier

Somewhat of a barrier

Moderate barrier

Extreme barrier

_______

Q. Is the low incidence rate of NTRK gene fusions acting as a barrier to your utilisation of Vitrakvi ?

Not a barrier

Somewhat of a barrier

Moderate barrier

Extreme barrier

_______

Q. In February, the FDA granted priority review for a similar drug called entrectinib, which could be approved later this year for the treatment of certain adult and paediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumours and patients with metastatic ROS1-positive non-small-cell lung cancer.

How would you rate your awareness of entrectinib?

Not at all aware

Slightly aware

Somewhat aware

Moderately aware

Extremely aware

_______

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.